Completed PHASE4 INTERVENTIONAL 2-arm NCT00396643

Indicated Prevention With Omega-3 Fatty Acids in Adolescents With 'At-Risk-Mental-State' for Psychosis

Indicated Prevention With Omega-3 Fatty Acids in Adolescents With 'At-Risk-Mental-State' for Psychosis: A Randomised, Double Blind, Placebo-Controlled Treatment Trial

Sponsor: Medical University of Vienna

Conditions Prodrome Schizophrenia

Interventions Omega 3 fatty acids

Updated 6 times since 2017 Last updated: Dec 20, 2007 Started: May 31, 2004 Primary completion: Jun 30, 2007 Completion: Jun 30, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE4 clinical study on Prodrome and Schizophrenia, this trial is completed. The trial is conducted by Medical University of Vienna and has accumulated 6 data snapshots since 2004. Psychiatric clinical trials are essential for establishing evidence-based treatment standards.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Feb 2017 — Jun 2018 [monthly]

Completed PHASE4

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE4

First recorded

May 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Medical University of Vienna
Stanley Medical Research Institute

Data source: Medical University of Vienna

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Vienna, Austria